<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Anesthesiol.</journal-id>
<journal-title>Frontiers in Anesthesiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Anesthesiol.</abbrev-journal-title>
<issn pub-type="epub">2813-480X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fanes.2023.1234567</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Anesthesiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Diagnosis and management of the patient with contaminated illicit drug poisoning</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Pino</surname><given-names>Richard M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref><uri xlink:href="https://loop.frontiersin.org/people/1714348/overview"/></contrib>
<contrib contrib-type="author"><name><surname>McGrew</surname><given-names>Patrick R.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label><sup>1</sup></label><addr-line>Department of Anesthesiology</addr-line>, <institution>Louisiana State University Health Sciences Center</institution>, <addr-line>New Orleans, LA</addr-line>, <country>United States</country></aff>
<aff id="aff2"><label><sup>2</sup></label><addr-line>Department of Surgery</addr-line>, <institution>Tulane University School of Medicine</institution>, <addr-line>New Orleans, LA</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by"><p><bold>Edited by:</bold> Marco Fiore, Universit&#x00E0; degli Studi della Campania &#x201C;Luigi Vanvitelli&#x201D;, Italy</p></fn>
<fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Etrusca Brogi, University of Pisa, Italy Juan Carlos Lopez-Delgado, Hospital Clinic of Barcelona, Spain</p></fn>
<corresp id="cor1"><label>&#x002A;</label><bold>Correspondence:</bold> Richard M. Pino <email>rpino1@lsuhsc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>12</day><month>10</month><year>2023</year></pub-date>
<pub-date pub-type="collection"><year>2023</year></pub-date>
<volume>2</volume><elocation-id>1234567</elocation-id>
<history>
<date date-type="received"><day>04</day><month>06</month><year>2023</year></date>
<date date-type="accepted"><day>29</day><month>09</month><year>2023</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2023 Pino and McGrew.</copyright-statement>
<copyright-year>2023</copyright-year><copyright-holder>Pino and McGrew</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>The diagnosis and management of poisoning is essential in critical care medicine. Traditionally, these conditions fall under the category of toxidromes that are the signs and symptoms associated with a particular class of poisons. However, there has been a steady increase in designer drugs and contaminants of recreational drugs themselves. Examples of adulterants in cocaine include the local anesthetic benzocaine and the anti-parasitic levamisole. This paper presents the clinical signs, laboratory findings, and treatment of patients who have been exposed to these substances.</p>
</abstract>
<kwd-group>
<kwd>adulterants</kwd>
<kwd>cocaine</kwd>
<kwd>toxicity</kwd>
<kwd>cathinones</kwd>
<kwd>cannabis</kwd>
<kwd>illicit drugs</kwd>
<kwd>xylazine</kwd>
</kwd-group><counts>
<fig-count count="0"/>
<table-count count="1"/><equation-count count="0"/><ref-count count="49"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-wrap><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Critical Care Anesthesiology</meta-value></custom-meta></custom-meta-wrap>
</article-meta>
</front>
<body><sec id="s1" sec-type="intro"><label>1.</label><title>Introduction</title>
<p>Admissions to the ICU related to substance abuse is, unfortunately, a common global issue. A recent study revealed that substance abuse was responsible for one quarter of ICU admissions and 23&#x0025; of total charges (<xref ref-type="bibr" rid="B1">1</xref>). Illicit drug use was associated with 13&#x0025; of these patients (<xref ref-type="bibr" rid="B1">1</xref>). Identification of the illicit drug on clinical presentation is often difficult. These substances often fall into multiple categories of toxidromes, the signs and symptoms associated with a particular class of poisons (<xref ref-type="bibr" rid="B2">2</xref>). Polysubstance abuse is common.</p>
<p>There has been the increasing use of &#x201C;adulterants&#x201D; that are legal substances which are added to these illicit drugs. This process, called &#x201C;cutting&#x201D;, is to either further enhance their effects or expand volume, both of which enhance the drug dealers&#x0027; profits (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Laboratory tests can confirm the most common illicit substances but often will not identify altered forms (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Our experience in a trauma center encompasses patients with substance abuse issues, but we had sparse knowledge of contaminants before caring for the patient in the clinical example below. In this paper we present examples illicit drug contaminants, a little-known subject for critical care physicians.</p>
<sec id="s1a"><label>1.1.</label><title>Cocaine</title>
<p>Cocaine is one of the most common illegal psychostimulant drugs (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). It is abused as either the water-soluble hydrochloride salt or a water-insoluble base known as &#x201C;freebase and crack&#x201D;. Cocaine blocks the transporters for dopamine, norepinephrine, and serotonin (<xref ref-type="bibr" rid="B8">8</xref>). With this blockade, there is continued stimulation by monoamines at the pre- and post- synapses to create euphoria that leads to addiction. Symptoms include tachycardia, hypertension, hyperthermia, and agitation (<xref ref-type="bibr" rid="B7">7</xref>). The long list of sequelae includes myocardial and cerebral infarctions. Acute kidney injury may be related to decreased renal blood flow from vascular smooth muscle constriction and rhabdomyolysis (<xref ref-type="bibr" rid="B9">9</xref>). Cutaneous vasculopathy with rheumatologic features including antineutrophil cytoplasmic antibodies (ANCA) can occur (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Adulterants in seized cocaine samples include levamisole, phenacetin, lidocaine, imidazole, and caffeine (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B13">13</xref>). Each of these compounds themselves will cause pathologic changes like cocaine making additional diagnoses difficult (<xref ref-type="table" rid="T1">Table&#x00A0;1</xref>).</p>
<table-wrap id="T1" position="float"><label>Table 1</label>
<caption><p>Acute effects of cocaine and cannabis contaminants.</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left">Illegal drug</th>
<th valign="top" align="center">Contaminant</th>
<th valign="top" align="center">Acute effects</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="6">Cocaine</td>
<td valign="top" align="left">Levamisole</td>
<td valign="top" align="left">Pulmonary HTN<break/>Agranulocytosis<break/>Cutaneous vasculopathy<break/>Negative inotropy</td>
</tr>
<tr>
<td valign="top" align="left">Lidocaine</td>
<td valign="top" align="left">Respiratory depression<break/>Seizures<break/>Vasodilatation</td>
</tr>
<tr>
<td valign="top" align="left">Phenacetin</td>
<td valign="top" align="left">Negative inotropy<break/>Hemolytic anemia<break/>Methemoglobinemia</td>
</tr>
<tr>
<td valign="top" align="left">Imidazole</td>
<td valign="top" align="left">Hepatotoxicity</td>
</tr>
<tr>
<td valign="top" align="left">H</td>
<td valign="top" align="left">Seizures<break/>Cardiac dysrhythmias<break/>hyperventilation</td>
</tr>
<tr>
<td valign="top" align="left">Benzocaine</td>
<td valign="top" align="left">Methemoglobinemia</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="2">Cannabis (inhaled)</td>
<td valign="top" align="left">Vitamin E and pine rosin</td>
<td valign="top" align="left">Diffuse alveolar damage<break/>Bronchiolitis<break/>Organizing pneumonia<break/>Pneumonitis</td>
</tr>
<tr>
<td valign="top" align="left">Brodifacoum</td>
<td valign="top" align="left">Bleeding</td>
</tr>
</tbody>
</table>
</table-wrap>
<p><bold>Levamisole</bold> is an antihelminthic in widespread veterinary use. It had been used as an adjuvant chemotherapy agent but was withdrawn from the US market in 2000 after side effects of agranulocytosis, cutaneous vasculopathy, and leukoencephalopathy were identified (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). Levamisole is the most widely used adulterant in up to 88&#x0025; of cocaine samples to improve its euphoric effects (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The mechanism for euphoria includes the metabolism to aminorex, an amphetamine-like substance once used as a diet drug. Aminorex was taken off the market secondary to pulmonary hypertension (<xref ref-type="bibr" rid="B17">17</xref>). Levamisole increases antibody production to various antigens by functioning as a hapten involved with isoimmune antineutrophil cell membrane antigens. Cutaneous manifestations include purpura, hemorrhagic bullae, and livedo reticularis (<xref ref-type="bibr" rid="B10">10</xref>). An immune-mediated mechanism has been suggested for eosinophilic inflammatory coronary artery pathology (<xref ref-type="bibr" rid="B18">18</xref>).</p>
<p><bold>Local anesthetics</bold> are added to cocaine since they have the same analgesic properties and cannot be detected as an adulterant by the drug user. Physicians are familiar with lidocaine used as an antidysrhythmic and local anesthetic controlled by the FDA and in the over-the-counter topical analgesics. What is likely unknown is that 99.9&#x0025; pure lidocaine and benzocaine powders can be purchased for &#x201C;research and development&#x201D; from common online sites without a prescription. The established maximum cumulative dose of intravenous lidocaine during treatment of ventricular dysrhythmias is 3&#x2005;mg/kg (<xref ref-type="bibr" rid="B19">19</xref>). As a local anesthetic injection without epinephrine the maximum dose is 4.5&#x2005;mg/kg (<xref ref-type="bibr" rid="B20">20</xref>). Clearly the drug dealers cutting cocaine with lidocaine greatly exceed this maximum. Overdose results in negative inotropy, vasodilatation, seizures, and respiratory depression (<xref ref-type="bibr" rid="B20">20</xref>). Hypercapnia and respiratory acidosis exacerbate central nervous system depression. A report from the United Kingdom indicated that 60&#x0025; of cocaine was adulterated with benzocaine (<xref ref-type="bibr" rid="B21">21</xref>). Benzocaine is rapidly absorbed across mucous membranes. Methemoglobinema results from the oxidation of the iron in hemoglobin to the ferric state. Cyanosis will be manifested after topical 150&#x2013;300&#x2005;mg, concentrations of methemoglobin result in metabolic acidosis, convulsions, and coma; levels about 70&#x0025; are lethal (<xref ref-type="bibr" rid="B21">21</xref>).</p>
<p><bold>Caffeine</bold> is the most widely used stimulant consumed by over 80&#x0025; of the population in the world. In moderate amounts of less than 400&#x2005;mg/day in healthy adults there is nominal toxicity (<xref ref-type="bibr" rid="B22">22</xref>). Toxic symptoms occur after injection of 1 gram, hospitalization is needed after 2&#x2005;g, and ingested doses of 5&#x2013;50&#x2005;g are fatal (<xref ref-type="bibr" rid="B23">23</xref>). It undergoes acetylation, oxidation, and N-demethylation in the liver (<xref ref-type="bibr" rid="B6">6</xref>). Therefore, alcohol and abused drugs in addition to cocaine potentiate the effects of caffeine. Caffeine enhances the reinforcing effects of cocaine and its motivational value (<xref ref-type="bibr" rid="B24">24</xref>). The combination of caffeine and cocaine makes users more likely to keep seeking out the drug than they would if they were addicted to cocaine alone.</p>
<p><bold>Phenacetin</bold> is an antipyretic and analgesic that is cleaved to form acetaminophen. It was removed from the market because of renal carcinogenicity. It is a negative inotrope, can generate methemoglobinemia through its metabolites, and can cause hemolytic anemia (<xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>). Phenacetin has no stimulant properties but is used as a cutting agent to increase the bulk of cocaine.</p>
<p><bold>Imidazole</bold> has fungicidal, antiprotozoal, and antihypertensive properties (<xref ref-type="bibr" rid="B26">26</xref>). The most common use is as a topic antifungal such as ketoconazole. It is part of the theophylline molecule derived from tea leaves and coffee beans and acts as a central nervous system stimulant. Imidazole itself is hepatotoxic via ATP depletion in cells with mitochondrial damage.</p>
</sec>
<sec id="s1b"><label>1.2.</label><title>Cannabis</title>
<p>Cannabis is the most widely used psychoactive substance. Through &#x0394;<sup>9</sup> -tetrahydrocannabinol (THC), cannabinoid receptors CB<sub>1</sub> in central and peripheral neurons are stimulated. Usually, the effects of decreased locomotor activity, cognitive impairment, analgesia, hypothermia, and appetite stimulation are considered of low toxicity but may be exacerbated when consumed in large doses (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>Cannabis can also be smoked using E-cigarettes containing &#x0394;<sup>8</sup> -tetrahydrocannabinol synthesized from cannabidiol (CBD) (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). Cutting agents in high levels, in addition to heavy metals leaching from the devices, are respiratory irritants (<xref ref-type="table" rid="T1">Table&#x00A0;1</xref>). Vitamin E acetate is a cutting agent that has been added to marijuana oils and has been associated to vaping-associated lung injury (EVALI) that includes diffuse alveolar damage, bronchiolitis with organizing pneumonia, and granulomatous pneumonitis (<xref ref-type="bibr" rid="B32">32</xref>). Pine rosin, a known lung irritant has been identified as an adulterant (<xref ref-type="bibr" rid="B31">31</xref>). Lung examination upon presentation does not correlate with the severity of the disease that can include diffuse alveolar damage, pneumonitis, and organizing pneumonia (<xref ref-type="bibr" rid="B30">30</xref>).</p>
<p>Synthesized cannabinols are dissolved in alcohol and acetone and sprayed on plant material. These are sold under a variety of names such as &#x201C;K2&#x201D; and &#x201C;Spice&#x201D;. They are classified as DEA Schedule 1 but compositions are continually modified to circumvent this DEA classification. Intoxication can be severe including psychosis, respiratory depression, cardiac arrest, nephrotoxity, hyperemesis, rhabdomyolysis, hyperthermia, seizures, and cerebral ischemia (<xref ref-type="bibr" rid="B33">33</xref>). The most lethal adulterant of synthetic cannabinoids is brodifacoum, a vitamin K-dependent antagonist (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). It is used to enhance the effects because of longer periods of lipid storage, hepatic metabolism, and slow release. Compared to the anticoagulation of warfarin it is 100 times greater and has a longer half-life of 20&#x2013;130 days (<xref ref-type="bibr" rid="B35">35</xref>).</p>
</sec>
<sec id="s1c"><label>1.3.</label><title>Synthetic cathinones</title>
<p>Synthetic cathinones are a group of potent designer drugs, often referred to as &#x201C;bath salts&#x201D;. Their effect is like 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) with the blockade of dopamine and norepinephrine uptake (<xref ref-type="bibr" rid="B36">36</xref>). Animal studies demonstrated that the synthetic cathinone methylenedioxypyrovalerone (MDPV) has greater potency than cocaine with respect to hyperactivity and cardiovascular stimulation (<xref ref-type="bibr" rid="B36">36</xref>). Neurologic symptoms include agitation, paranoia, hallucinations, myoclonus, and psychosis. In addition to hyperthermia, hypertension, and tachycardia liver failure, kidney failure, and compartment syndrome with rhabdomyolysis have been reported (<xref ref-type="bibr" rid="B37">37</xref>).</p>
</sec>
<sec id="s1d"><label>1.4.</label><title>Xylazine</title>
<p>Xylazine is a veterinary drug used as a sedative, analgesic, and muscle relaxant (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). It has a structure that is similar to phenothiazines, tricyclic antidepressants, and clonidine. As for clonidine, it is a potent central &#x03B1;<sub>2</sub>-receptor agonist that will decrease the release of norepinephrine and dopamine. The intended use, in addition to cutting, is to enhance the sedation and analgesia of the illicit drug. Xylazine was first identified as a cutting agent in Puerto Rico and has adulterated heroin and cocaine and (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). The contaminant of fentanyl with xylazine has been considered as the deadliest drug threat in the United States (<xref ref-type="bibr" rid="B40">40</xref>). More than 90&#x0025; of illicit drug samples in Philadelphia are positive for xylazine with the street names &#x201C;tranq&#x201D;, &#x201C;tranq dope&#x201D;, and &#x201C;zombie drug&#x201D; (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>The most noted side effect of xylazine is characteristic necrotic skin ulcers that are likely caused by vasoconstriction and poor skin perfusion (<xref ref-type="bibr" rid="B42">42</xref>). Based on case reports, the effects of overdosage include hypotension, bradycardia, hyperglycemia, areflexia, elevated cardiac enzymes, coma, and respiratory failure (<xref ref-type="bibr" rid="B43">43</xref>).</p>
</sec>
</sec>
<sec id="s2"><label>2.</label><title>Management of complications</title>
<p>The acuity of substance abuse patients admitted to the ICU is complex but well within the realm of care addressed by intensive care physicians.</p>
<p><bold>Respiratory</bold> embarrassment may be related to the overdose suppression of spontaneous ventilation or pulmonary parenchymal pathology as found with EVALI. The need for tracheal intubation and mechanical ventilation is straight-forward for most of these patients and often performed before the patient arrives in the ICU. Systemic glucocorticoid therapy was shown to be effective in the treatment of EVALI (<xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>As many of the patients are polysubstance abusers, treatment of the drug effects, as well as underlying <bold>psychiatric issues</bold>, may require the use of multiple agents such as quetiapine and benzodiazepines (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B44">44</xref>). For severe withdrawal, high dose lorazepam alone was ineffective when compared to the synergistic actions of propofol infusions with reduced lorazepam doses (<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p><bold>Acute kidney injury</bold> treatment is largely supportive (<xref ref-type="bibr" rid="B9">9</xref>). Restoration intravascular volume is essential since acute tubular necrosis may be related to hypovolemia resulting from poor intake, diarrhea, and vomiting. The latter is often associated with altered electrolyte levels. CPK&#x0027;s should be monitored to reveal rhabdomyolysis that may not be evident on physical examination. Dialysis may be necessary (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p><bold>Cardiovascular toxicity</bold>, especially with cocaine, is the most difficult life-threatening processes requiring ICU care. The evidence for pharmacologic treatment is limited for the management of tachycardia, hypertension, dysrhythmia, and coronary vasospasm in a comprehensive review of the literature (<xref ref-type="bibr" rid="B46">46</xref>). Labetalol and carvedilol will control hypertension and tachycardia. Nitroglycerin is recommended for cocaine-associated chest pain and vasospasm with the risk of tachycardia (<xref ref-type="bibr" rid="B47">47</xref>). Dexmedetomidine will control hypertension at high doses (1.0&#x2005;&#x00B5;g/kg) with the possibility of bradycardia (<xref ref-type="bibr" rid="B48">48</xref>). Beta blockers will decrease heart rate as expected but are used cautiously to prevent unopposed hypertension. Esmolol is effective but will cause more hypotension when comparted to other beta blockers. The sequelae of hypertension and tachycardia related to hypoxemia from methemoglobinemia require treatment especially for patients with cardiovascular disease or levels of &#x2265;30&#x0025; by co-oximetry (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Methylene blue (1&#x0025;, 1&#x2013;2&#x2005;mg/kg) over 5&#x2005;min with repeat every 30&#x2005;min is the usual therapy. Hyperbaric oxygen treat has been reported for methemoglobinemia that was refractive to methylene blue. The cardiac effects of caffeine overdose are ameliorated with dialysis.</p>
<p>The extensive <bold>skin necrosis</bold> and infection related to xylazine is treated with appropriate antibiotics, topical treatment, and surgical debridement if needed.</p>
</sec>
<sec id="s3"><label>3.</label><title>Take home message</title>
<p>The management of patients requiring ICU care for toxicities related to substance abuse is challenging. The clinical pathophysiology may be related to a single drug, multiple drugs, and often adulterated illegal agents. For many of these patients, such as the one described above, supportive critical care is an easily identifiable task but comes with the cost of extensive resource management. It is critical to consider adulterants that would cause unexpected findings such as methemoglobinemia, lidocaine toxicity, necrotic skin lesions, or rhabdomyolysis in the absence of trauma or a compartment syndrome.</p>
</sec>
</body>
<back>
<sec id="s4" sec-type="author-contributions"><title>Author contributions</title>
<p>PM and RP equally contributed to the research, writing, and editing of this manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s5" sec-type="COI-statement"><title>Conflict of interest</title>
<p>The author RP declared that he was an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision. The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s6" sec-type="disclaimer"><title>Publisher&#x0027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list><title>References</title>
<ref id="B1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westerhausen</surname><given-names>D</given-names></name><name><surname>Perkins</surname><given-names>AJ</given-names></name><name><surname>Conley</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>BA</given-names></name><name><surname>Farber</surname><given-names>M</given-names></name></person-group>. <article-title>Burden of substance abuse-related admissions to the medical ICU</article-title>. <source>Chest</source>. (<year>2020</year>) <volume>157</volume>:<fpage>61</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2019.08.2180</pub-id><pub-id pub-id-type="pmid">31494083</pub-id></citation></ref>
<ref id="B2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holstege</surname><given-names>CP</given-names></name><name><surname>Borek</surname><given-names>HA</given-names></name></person-group>. <article-title>Toxidromes</article-title>. <source>Crit Care Clin</source>. (<year>2012</year>) <volume>28</volume>:<fpage>479</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccc.2012.07.008</pub-id><pub-id pub-id-type="pmid">22998986</pub-id></citation></ref>
<ref id="B3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arango-Meri&#x00F1;o</surname><given-names>L</given-names></name><name><surname>Quevedo-Castro</surname><given-names>C</given-names></name><name><surname>Mancera-Barros</surname><given-names>J</given-names></name><name><surname>Sarmiento-Guti&#x00E9;rrez</surname><given-names>A</given-names></name><name><surname>Arana</surname><given-names>VA</given-names></name><name><surname>Granados-Reyes</surname><given-names>J</given-names></name></person-group>. <article-title>Cutting agents in cocaine: a temporal study of the period 2015&#x2013;2017 in the northern region of Columbia</article-title>. <source>Forensic Sci Int</source>. (<year>2021</year>) <volume>327</volume>:<fpage>110911</fpage>. <pub-id pub-id-type="doi">10.1016/j.forsciint.2021.110911</pub-id></citation></ref>
<ref id="B4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kudlacek</surname><given-names>O</given-names></name><name><surname>Hofmaier</surname><given-names>T</given-names></name><name><surname>Luf</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>FP</given-names></name><name><surname>Stockner</surname><given-names>T</given-names></name><name><surname>Nagy</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Cocaine adulteration</article-title>. <source>J Chem Neuroanat</source>. (<year>2017</year>) <volume>83&#x2013;84</volume>:<fpage>75</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchemneu.2017.06.001</pub-id></citation></ref>
<ref id="B5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>DA</given-names></name><name><surname>George</surname><given-names>MP</given-names></name><name><surname>Bluth</surname><given-names>MH</given-names></name></person-group>. <article-title>Toxicology in addiction medicine</article-title>. <source>Clin Lab Med</source>. (<year>2016</year>) <volume>36</volume>:<fpage>685</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.cll.2016.07.009</pub-id><pub-id pub-id-type="pmid">27842786</pub-id></citation></ref>
<ref id="B6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>RR</given-names></name><name><surname>Faria</surname><given-names>AC</given-names></name><name><surname>Brito-da-Costa</surname><given-names>AM</given-names></name><name><surname>Carmo</surname><given-names>H</given-names></name><name><surname>Mladenka</surname><given-names>P</given-names></name><name><surname>DaSilva</surname><given-names>DD</given-names></name><etal/></person-group> <article-title>Cocaine: an updated overview on chemistry, detection, biokinetics, and pharmacotoxicological aspects including abuse pattern</article-title>. <source>Toxins (Basel)</source>. (<year>2022</year>) <volume>14</volume>:<fpage>278</fpage>. <pub-id pub-id-type="doi">10.3390/toxins14040278</pub-id><pub-id pub-id-type="pmid">35448887</pub-id></citation></ref>
<ref id="B7"><label>7.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>JL</given-names></name></person-group>. <article-title>Poisonings</article-title>. In: <person-group person-group-type="editor"><name><surname>Parillo</surname><given-names>JE</given-names></name><name><surname>Dellinger</surname><given-names>P</given-names></name></person-group>, editors. <source>Critical care medicine</source>. <edition>5th ed.</edition> <publisher-loc>Philadelphia, PA, USA</publisher-loc>: <publisher-name>Elsevier</publisher-name> (<year>2019</year>). p. <fpage>1093</fpage>&#x2013;<lpage>110</lpage>.</citation></ref>
<ref id="B8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>AS</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Jorgensen</surname><given-names>TN</given-names></name><name><surname>Sorensen</surname><given-names>L</given-names></name><name><surname>Eriksen</surname><given-names>J</given-names></name><name><surname>Loland</surname><given-names>CJ</given-names></name><etal/></person-group> <article-title>SLC6 neurotransmitter transporters: structure, function, and regulation</article-title>. <source>Pharmacol Rev</source>. (<year>2011</year>) <volume>63</volume>:<fpage>585</fpage>&#x2013;<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1124/pr.108.000869</pub-id><pub-id pub-id-type="pmid">21752877</pub-id></citation></ref>
<ref id="B9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pendergraft</surname><given-names>WF</given-names></name><name><surname>Herlitz</surname><given-names>LC</given-names></name><name><surname>Thornley-Brown</surname><given-names>D</given-names></name><name><surname>Rosner</surname><given-names>M</given-names></name><name><surname>Niles</surname><given-names>JL</given-names></name></person-group>. <article-title>Nephrotoxic effects of common and emerging drugs of abuse</article-title>. <source>Clin J Am Soc Nephrol</source>. (<year>2014</year>) <volume>9</volume>:<fpage>1996</fpage>&#x2013;<lpage>2005</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.00360114</pub-id><pub-id pub-id-type="pmid">25035273</pub-id></citation></ref>
<ref id="B10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milman</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name></person-group>. <article-title>Cutaneous vasculopathy associated with cocaine use</article-title>. <source>Arthritis Care Res</source>. (<year>2011</year>) <volume>63</volume>:<fpage>1195</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1002/acr.20483</pub-id></citation></ref>
<ref id="B11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bros&#x00E9;us</surname><given-names>J</given-names></name><name><surname>Gentile</surname><given-names>N</given-names></name><name><surname>Bonadio</surname><given-names>F</given-names></name><name><surname>Garcia</surname><given-names>L</given-names></name><name><surname>Gast&#x00E9;</surname><given-names>L</given-names></name><name><surname>Esseiva</surname><given-names>P</given-names></name></person-group>. <article-title>Qualitative, quantitative and temporal study of cutting agents for cocaine and heroin over 9 years</article-title>. <source>Forensic Sci Int</source>. (<year>2015</year>) <volume>257</volume>:<fpage>307</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.forsciint.2015.09.014</pub-id></citation></ref>
<ref id="B12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Meys</surname><given-names>F</given-names></name></person-group>. <article-title>Analysis of illicit cocaine and heroin samples seized in Luxembourg from 2005 to 2010</article-title>. <source>Forensic Sci Int</source>. (<year>2011</year>) <volume>212</volume>:<fpage>242</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.forsciint.2011.06.027</pub-id><pub-id pub-id-type="pmid">21767923</pub-id></citation></ref>
<ref id="B13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zacca</surname><given-names>J</given-names></name><name><surname>Botelho</surname><given-names>&#x00C9;</given-names></name><name><surname>Vieira</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>F</given-names></name><name><surname>Ferreira</surname><given-names>L</given-names></name><name><surname>Maldaner</surname><given-names>A</given-names></name></person-group>. <article-title>Brazilian federal police drug chemical profiling&#x2014;the PeQui project</article-title>. <source>Sci Justice</source>. (<year>2014</year>) <volume>54</volume>:<fpage>300</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.scijus.2014.02.008</pub-id><pub-id pub-id-type="pmid">25002048</pub-id></citation></ref>
<ref id="B14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auffenberg</surname><given-names>C</given-names></name><name><surname>Rosenthal</surname><given-names>LJ</given-names></name><name><surname>Dresner</surname><given-names>N</given-names></name></person-group>. <article-title>Levamisole: a common cocaine adulterant with life-threatening side effects</article-title>. <source>Psychosomatics</source>. (<year>2013</year>) <volume>54</volume>:<fpage>590</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.psym.2013.02.012</pub-id><pub-id pub-id-type="pmid">23756121</pub-id></citation></ref>
<ref id="B15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>JA</given-names></name><name><surname>Lavonas</surname><given-names>EJ</given-names></name></person-group>. <article-title>Agranulocytosis and other consequences due to the use of illicit cocaine contaminated with levamisole</article-title>. <source>Curr Opin Hematol</source>. (<year>2021</year>) <volume>19</volume>:<fpage>27</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0b013e32834da9ef</pub-id></citation></ref>
<ref id="B16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Midthun</surname><given-names>KM</given-names></name><name><surname>Nelson</surname><given-names>LS</given-names></name><name><surname>Logan</surname><given-names>BK</given-names></name></person-group>. <article-title>Levamisole-a toxic adulterant in illicit drug preparations: a review</article-title>. <source>Ther Drug Monit</source>. (<year>2021</year>) <volume>43</volume>:<fpage>221</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/FTD.0000000000000851</pub-id><pub-id pub-id-type="pmid">33298746</pub-id></citation></ref>
<ref id="B17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofmaier</surname><given-names>T</given-names></name><name><surname>Luf</surname><given-names>A</given-names></name><name><surname>Seddik</surname><given-names>A</given-names></name><name><surname>Stockner</surname><given-names>T</given-names></name><name><surname>Holy</surname><given-names>M</given-names></name><name><surname>Freissmuth</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters</article-title>. <source>Neurochem Int</source>. (<year>2014</year>) <volume>73</volume>:<fpage>32</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2013.11.010</pub-id><pub-id pub-id-type="pmid">24296074</pub-id></citation></ref>
<ref id="B18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michaud</surname><given-names>K</given-names></name><name><surname>Grfabherr</surname><given-names>S</given-names></name><name><surname>Shiferaw</surname><given-names>K</given-names></name><name><surname>Doenz</surname><given-names>F</given-names></name><name><surname>Augsburger</surname><given-names>M</given-names></name><name><surname>Mangin</surname><given-names>P</given-names></name></person-group>. <article-title>Acute coronary syndrome after levamisole-adultered cocaine abuse</article-title>. <source>J Forensic Leg Med</source>. (<year>2014</year>) <volume>21</volume>:<fpage>48</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.jflm.2013.10.015</pub-id><pub-id pub-id-type="pmid">24365689</pub-id></citation></ref>
<ref id="B19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panchal</surname><given-names>AR</given-names></name><name><surname>Berg</surname><given-names>KM</given-names></name><name><surname>Kudenchuk</surname><given-names>PJ</given-names></name><name><surname>Del Rios</surname><given-names>M</given-names></name><name><surname>Hirsch</surname><given-names>KG</given-names></name><name><surname>Link</surname><given-names>MS</given-names></name><etal/></person-group> <article-title>2018 American heart association focused update on advanced cardiovascular life support use of antiarrhythmic drugs during and immediately after cardiac arrest: an update to the American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care</article-title>. <source>Circulation</source>. (<year>2018</year>) <volume>138</volume>:<fpage>e740</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000613</pub-id><pub-id pub-id-type="pmid">30571262</pub-id></citation></ref>
<ref id="B20"><label>20.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lirk</surname><given-names>P</given-names></name><name><surname>Berde</surname><given-names>CB</given-names></name></person-group>. <article-title>Local anesthetics</article-title>. In: <person-group person-group-type="editor"><name><surname>Parillo</surname><given-names>JE</given-names></name><name><surname>Dellinger</surname><given-names>P</given-names></name></person-group>, editors. <source>Critical care medicine</source>. <edition>5th ed.</edition> <publisher-loc>Philadelphia, PA, USA</publisher-loc>: <publisher-name>Elsevier</publisher-name> (2019). p. <fpage>865</fpage>&#x2013;<lpage>90</lpage>.</citation></ref>
<ref id="B21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chakladar</surname><given-names>A</given-names></name><name><surname>Willers</surname><given-names>JW</given-names></name><name><surname>Pereskokova</surname><given-names>E</given-names></name><name><surname>Beaumont</surname><given-names>P</given-names></name><name><surname>Uncles</surname><given-names>DR</given-names></name></person-group>. <article-title>White powder, blue patients: methaemoglobinaemia associated with benzocaine-adulterated cocaine</article-title>. <source>Resuscitation</source>. (<year>2010</year>) <volume>81</volume>:<fpage>138</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.resuscitation.2009.10.019</pub-id><pub-id pub-id-type="pmid">19926196</pub-id></citation></ref>
<ref id="B22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>C</given-names></name></person-group>. <article-title>The clinical toxicology of caffeine: a review and case study</article-title>. <source>Toxicol Rep</source>. (<year>2018</year>) <volume>5</volume>:<fpage>1140</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxrep.2018.11.002</pub-id><pub-id pub-id-type="pmid">30505695</pub-id></citation></ref>
<ref id="B23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonsignore</surname><given-names>A</given-names></name><name><surname>Sblano</surname><given-names>S</given-names></name><name><surname>Pozzi</surname><given-names>F</given-names></name><name><surname>Ventura</surname><given-names>F</given-names></name><name><surname>Dell&#x2019;Erba</surname><given-names>A</given-names></name><name><surname>Palmiere</surname><given-names>C</given-names></name></person-group>. <article-title>A case of suicide by ingestion of caffeine</article-title>. <source>Forensic Sci Med Pathol</source>. (<year>2014</year>) <volume>10</volume>:<fpage>448</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s12024-014-9571-6</pub-id><pub-id pub-id-type="pmid">24771479</pub-id></citation></ref>
<ref id="B24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>JP</given-names></name><name><surname>Scorza</surname><given-names>C</given-names></name><name><surname>Serra</surname><given-names>GP</given-names></name><name><surname>Perra</surname><given-names>V</given-names></name><name><surname>Galvalisi</surname><given-names>M</given-names></name><name><surname>Abin-Carriquiry</surname><given-names>JA</given-names></name><etal/></person-group> <article-title>Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value</article-title>. <source>Psychoparmacology</source>. (<year>2016</year>) <volume>233</volume>:<fpage>2879</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-016-4320-z</pub-id></citation></ref>
<ref id="B25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>L</given-names></name><name><surname>Gordge</surname><given-names>L</given-names></name><name><surname>Dargan</surname><given-names>PI</given-names></name><name><surname>Wood</surname><given-names>DM</given-names></name></person-group>. <article-title>Methaemoglobinaemia associated with the use of cocaine and volatile nitrites as recreational drugs: a review</article-title>. <source>Br J Clin Pharmacol</source>. (<year>2011</year>) <volume>72</volume>:<fpage>18</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03950.x</pub-id><pub-id pub-id-type="pmid">21352269</pub-id></citation></ref>
<ref id="B26"><label>26.</label><citation citation-type="book"><collab>IARC Working Group on the Evaluation of Carcinogenic Risks to Humans</collab>. <article-title>Pharmaceuticals</article-title>. <source>IARC Monographs on the evaluation of carcinogenic risks to humans, No.100A.PHENACETIN</source>. <publisher-loc>Lyon (FR)</publisher-loc>: <publisher-name>International Agency for Research on Cancer</publisher-name> (<year>2012</year>). p. <fpage>377</fpage>&#x2013;<lpage>98</lpage>. <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK304337/#:&#x223C;:text=IARC%20Working%20Group%20on,nih.gov/books/NBK304337/">https://www.ncbi.nlm.nih.gov/books/NBK304337/&#x0023;:&#x223C;:text&#x003D;IARC&#x0025;20Working&#x0025;20Group&#x0025;20on,nih.gov/books/NBK304337/</ext-link></citation></ref>
<ref id="B27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haegler</surname><given-names>P</given-names></name><name><surname>Joerin</surname><given-names>L</given-names></name><name><surname>Kr&#x00E4;henb&#x00FC;hl</surname><given-names>S</given-names></name><name><surname>Bouibir</surname><given-names>J</given-names></name></person-group>. <article-title>Hepatocellular toxicology of imidazole and triazole antimicotic agents</article-title>. <source>Toxicol Sci</source>. (<year>2017</year>) <volume>157</volume>:<fpage>183</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfx029</pub-id><pub-id pub-id-type="pmid">28329820</pub-id></citation></ref>
<ref id="B28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Scholz</surname><given-names>I</given-names></name><name><surname>Mueller</surname><given-names>L</given-names></name><name><surname>Exadaktylos</surname><given-names>AK</given-names></name><name><surname>Ceschi</surname><given-names>A</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><etal/></person-group> <article-title>Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland</article-title>. <source>Drug Alcohol Depend</source>. (<year>2020</year>) <volume>206</volume>:<fpage>107726</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.107726</pub-id><pub-id pub-id-type="pmid">31735534</pub-id></citation></ref>
<ref id="B29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>K</given-names></name><name><surname>Hsueh</surname><given-names>A</given-names></name><name><surname>Kendric</surname><given-names>K</given-names></name><name><surname>Kunihira</surname><given-names>K</given-names></name><name><surname>Siddiqi</surname><given-names>N</given-names></name><name><surname>Phan</surname><given-names>TH</given-names></name><etal/></person-group> <article-title>Unwitting adult marijuana poisoning: a case series</article-title>. <source>Clin Toxicol</source>. (<year>2021</year>) <volume>59</volume>:<fpage>913</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/15563650.2021.1891241</pub-id></citation></ref>
<ref id="B30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cobb</surname><given-names>NK</given-names></name><name><surname>Solanki</surname><given-names>JN</given-names></name></person-group>. <article-title>E-cigarettes, vaping devices, and acute lung injury</article-title>. <source>Respir Care</source>. (<year>2020</year>) <volume>65</volume>:<fpage>713</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4187/respcare.07733</pub-id><pub-id pub-id-type="pmid">32345762</pub-id></citation></ref>
<ref id="B31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meehan-Atrash</surname><given-names>J</given-names></name><name><surname>Rahman</surname><given-names>I</given-names></name></person-group>. <article-title>Novel &#x0394;<sup>8</sup>-tetrahydrocannabinol vaporizers contain unlabeled adulterants, unintended byproducts of chemical synthesis, and heavy metals</article-title>. <source>Chem Res Toxicol</source>. (<year>2022</year>) <volume>35</volume>:<fpage>73</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.1c00388</pub-id><pub-id pub-id-type="pmid">34889611</pub-id></citation></ref>
<ref id="B32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Layden</surname><given-names>JE</given-names></name><name><surname>Ghinai</surname><given-names>I</given-names></name><name><surname>Pray</surname><given-names>I</given-names></name><name><surname>Kimball</surname><given-names>A</given-names></name><name><surname>Layer</surname><given-names>M</given-names></name><name><surname>Tenforde</surname><given-names>MW</given-names></name><etal/></person-group> <article-title>Pulmonary illness related to e-cigarette use in Illinois and Wisconsin&#x2014;final report</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>903</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1911614</pub-id><pub-id pub-id-type="pmid">31491072</pub-id></citation></ref>
<ref id="B33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>ZD</given-names></name></person-group>. <article-title>Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal</article-title>. <source>Curr Psychiatry Rep</source>. (<year>2016</year>) <volume>18</volume>:<fpage>52</fpage>. <pub-id pub-id-type="doi">10.1007/s11920-016-0694-1</pub-id><pub-id pub-id-type="pmid">27074934</pub-id></citation></ref>
<ref id="B34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Bhagia</surname><given-names>G</given-names></name></person-group>. <article-title>Brodifacoum-laced synthetic marijuana toxicity: a fight against time</article-title>. <source>Am J Case Rep</source>. (<year>2020</year>) <volume>21</volume>:<fpage>e927111</fpage>. <pub-id pub-id-type="doi">10.12659/AJCR.927111</pub-id><pub-id pub-id-type="pmid">33132381</pub-id></citation></ref>
<ref id="B35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>CH</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>EL</given-names></name></person-group>. <article-title>Hemorrhagic soft tissue upper airway obstruction from brodifacoum-contaminated synthetic cannabinoid</article-title>. <source>J Emerg Med</source>. (<year>2019</year>) <volume>57</volume>:<fpage>47</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jemermed.2019.03.007</pub-id><pub-id pub-id-type="pmid">31078349</pub-id></citation></ref>
<ref id="B36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>MH</given-names></name><name><surname>Partilla</surname><given-names>JS</given-names></name><name><surname>Lehner</surname><given-names>KR</given-names></name><name><surname>Thorndike</surname><given-names>EB</given-names></name><name><surname>Hoffman</surname><given-names>AF</given-names></name><name><surname>Holy</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone(MDPV), a principal constituent of psychoactive &#x201C;bath salts&#x201D; products</article-title>. <source>Neuropsychopharmacology</source>. (<year>2013</year>) <volume>38</volume>:<fpage>552</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2012.204</pub-id><pub-id pub-id-type="pmid">23072836</pub-id></citation></ref>
<ref id="B37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>German</surname><given-names>CL</given-names></name><name><surname>Fleckenstein</surname><given-names>AE</given-names></name><name><surname>Hanson</surname><given-names>GR</given-names></name></person-group>. <article-title>Bath salts and synthetic cathinones: an emerging designer drug phenomenon</article-title>. <source>Life Sci</source>. (<year>2014</year>) <volume>97</volume>:<fpage>2</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2013.07.023</pub-id><pub-id pub-id-type="pmid">23911668</pub-id></citation></ref>
<ref id="B38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Col&#x00F3;n</surname><given-names>K</given-names></name><name><surname>Chavez-Arias</surname><given-names>C</given-names></name><name><surname>Diaz-Alcal&#x00E0;</surname><given-names>JE</given-names></name><name><surname>Mart&#x00ED;nez</surname><given-names>MA</given-names></name></person-group>. <article-title>Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature</article-title>. <source>Forensic Sci Int</source>. (<year>2014</year>) <volume>240</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.forsciint.2014.03.015</pub-id></citation></ref>
<ref id="B39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayub</surname><given-names>S</given-names></name><name><surname>Parnia</surname><given-names>S</given-names></name><name><surname>Poddar</surname><given-names>K</given-names></name><name><surname>Bachu</surname><given-names>AK</given-names></name><name><surname>Sullivan</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>AM</given-names></name><etal/></person-group> <article-title>Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications</article-title>. <source>Cureus</source>. (<year>2023</year>) <volume>15</volume>:<fpage>e36864</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.36864</pub-id><pub-id pub-id-type="pmid">37009344</pub-id></citation></ref>
<ref id="B40"><label>40.</label><citation citation-type="other"><comment>United States Drug Enforcement Administration. DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine [undated]</comment>. <ext-link ext-link-type="uri" xlink:href="https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine">https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine</ext-link></citation></ref>
<ref id="B41"><label>41.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>J</given-names></name></person-group>. <article-title>Tranq Dope: Animal Sedative Mixed With Fentanyl Brings Fresh Horror to U.S. Drug Zones</article-title>. (<year>2023</year>) <publisher-name>The New York Times</publisher-name>. <ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/2023/01/07/health/fentanyl-xylazine-drug.html">https://www.nytimes.com/2023/01/07/health/fentanyl-xylazine-drug.html</ext-link></citation></ref>
<ref id="B42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malayala</surname><given-names>SV</given-names></name><name><surname>Papudesia</surname><given-names>BN</given-names></name><name><surname>Bobb</surname><given-names>R</given-names></name><name><surname>Wimbush</surname><given-names>A</given-names></name></person-group>. <article-title>Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA</article-title>. <source>Cureus</source>. (<year>2022</year>) <volume>19</volume>:<fpage>e28160</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.28160</pub-id></citation></ref>
<ref id="B43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spoerke</surname><given-names>DG</given-names></name><name><surname>Grimes</surname><given-names>MJ</given-names></name><name><surname>Honea</surname><given-names>BN</given-names></name></person-group>. <article-title>Human overdose with the veterinary tranquilizer xylazine</article-title>. <source>Am J Emerg Med</source>. (<year>1986</year>) <volume>4</volume>:<fpage>222</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/0735-6757(86)90070-7</pub-id><pub-id pub-id-type="pmid">3964361</pub-id></citation></ref>
<ref id="B44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Connors</surname><given-names>NJ</given-names></name><name><surname>Alsakha</surname><given-names>A</given-names></name><name><surname>Larocque</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>RS</given-names></name><name><surname>Landry</surname><given-names>T</given-names></name><name><surname>Gosselin</surname><given-names>S</given-names></name></person-group>. <article-title>Antipsychotics for the treatment of sympathomimetic toxicity: a systemic review</article-title>. <source>Am J Emerg Med</source>. (<year>2019</year>) <volume>37</volume>:<fpage>1880</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2019.01.001</pub-id><pub-id pub-id-type="pmid">30639129</pub-id></citation></ref>
<ref id="B45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>K</given-names></name><name><surname>Gowda</surname><given-names>RM</given-names></name><name><surname>Jani</surname><given-names>K</given-names></name><name><surname>Zewedie</surname><given-names>W</given-names></name><name><surname>Ute</surname><given-names>R</given-names></name></person-group>. <article-title>Propofol combined with lorazepam for severe poly substance misuse and withdrawal states in intensive care unit: a case series and review</article-title>. <source>Emerg Med J</source>. (<year>2004</year>) <volume>21</volume>:<fpage>632</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/emj.2003.007526</pub-id><pub-id pub-id-type="pmid">15333553</pub-id></citation></ref>
<ref id="B46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>JR</given-names></name><name><surname>Garber</surname><given-names>D</given-names></name><name><surname>Laurin</surname><given-names>EG</given-names></name><name><surname>Albertson</surname><given-names>TE</given-names></name><name><surname>Derlet</surname><given-names>RW</given-names></name><name><surname>Amsterdam</surname><given-names>EA</given-names></name><etal/></person-group> <article-title>Treatment of cocaine cardiovascular toxicity: a systemic review</article-title>. <source>Clin Toxicol</source>. (<year>2016</year>) <volume>54</volume>:<fpage>345</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.3109/15563650.2016.1142090</pub-id></citation></ref>
<ref id="B47"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>EA</given-names></name><name><surname>Wenge</surname><given-names>NK</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Casey</surname><given-names>DE</given-names></name><name><surname>Ganiats</surname><given-names>TG</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><etal/></person-group> <article-title>AHA/ACC guideline for the management of patients with non-ST segment elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines</article-title>. <source>J Am Coll Cardiol</source>. (<year>2014</year>) <volume>64</volume>:<fpage>e139</fpage>&#x2013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2014.09.017</pub-id><pub-id pub-id-type="pmid">25260718</pub-id></citation></ref>
<ref id="B48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kontak</surname><given-names>AC</given-names></name><name><surname>Victor</surname><given-names>RG</given-names></name><name><surname>Vongpatanasin</surname><given-names>W</given-names></name></person-group>. <article-title>Dexmedetomidine as a novel countermeasure for cocaine-induced central sympathoexcitation in cocaine-addicted humans</article-title>. <source>Hypertension</source>. (<year>2013</year>) <volume>61</volume>:<fpage>388</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.112.203554</pub-id><pub-id pub-id-type="pmid">23283356</pub-id></citation></ref>
<ref id="B49"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cefalu</surname><given-names>JN</given-names></name><name><surname>Joshi</surname><given-names>TV</given-names></name><name><surname>Spalitta</surname><given-names>MJ</given-names></name><name><surname>Kadi</surname><given-names>CJ</given-names></name><name><surname>Diaz</surname><given-names>JH</given-names></name><name><surname>Eskander</surname><given-names>JP</given-names></name><etal/></person-group> <article-title>Methemoglobinemia in the operating room and intensive care unit: early recognition, pathophysiology, and management</article-title>. <source>Adv Ther</source>. (<year>2020</year>) <volume>37</volume>:<fpage>1714</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/s12325-020-01282-5</pub-id><pub-id pub-id-type="pmid">32193811</pub-id></citation></ref></ref-list>
</back>
</article>